Zuclopenthixol Short-acting Intramuscular Injection
Form: Short-acting Intramuscular Injection
Strength: 50 mg/mL
Reference Brands: Clopixol-Acuphase®
Category: Antipsychotropic Drugs
Zuclopenthixol short-acting intramuscular injection, commonly used in acute psychosis and agitation, is not currently approved by the FDA in the United States but is available in several EU markets under Clopixol-Acuphase. In the EU, it follows EMA regulatory standards for parenteral antipsychotics, requiring GMP compliance, stability data, and clinical justification for emergency psychiatric use. U.S. registration would require a detailed regulatory strategy, including an IND or 505(b)(2) approach. To explore other dosage forms, strengths, and dossier-ready Zuclopenthixol IM injection products, visit Pharmatradz.com — your trusted global B2B platform for API and finished formulations.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Risperidone Long-Acting Injection
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Form: Long-Acting Injection
Reference Brands: Risperdal Consta(US &EU)
View Details Get Enquiry
Zuclopenthixol ong-acting IM Injection (Depot)
Strength: 200 mg/mL, 500 mg/mL
Form: Long-acting IM Injection (Depot)
Reference Brands: Clopixol Depot®(US)
View Details Get Enquiry
Zuclopenthixol tablets
Strength: 10 mg, 25 mg, 40 mg
Form: Oral Tablets
Reference Brands: Clopixol®(EU)
View Details Get Enquiry
Pimozide Tablets
Strength: 1 mg, 2 mg, 4 mg
Form: Oral Tablets
Reference Brands: Orap®(US & EU)
View Details Get Enquiry